Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | CCR2 | P41597 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.39 |
| ▸ | TCF7L2 | Q9NQB0 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | WHR1 | P49842 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201687 | 0.92 | ADRA2A (0.40) | APPBCHEACHECCR2KDM4E | |
| Trifluoroacetic Acid SCHEMBL5530304 | 0.79 | EPHX2 (0.57) | APPBCHEACHEEPHX2CTNNB1 | |
| SCHEMBL5524385 | 0.75 | MCHR1 (0.42) | NPY5R | |
| SCHEMBL5521145 | 0.73 | MCHR1 (0.45) | NPY5R | |
| SCHEMBL5528028 | 0.73 | MCHR1 (0.48) | NPY5R | |
| SCHEMBL5532977 | 0.73 | MCHR1 (0.46) | NPY5R | |
| Trifluoroacetic Acid SCHEMBL4201680 | 0.72 | EPHX2 (0.49) | APPBCHEACHEEPHX2NPY5R | |
| SCHEMBL5528648 | 0.71 | WHR1 (0.50) | APPBCHEACHEEPHX2WHR1 | |
| SCHEMBL4217522 | 0.69 | EPHX2 (0.51) | APPBCHEACHEEPHX2NPY5R | |
| SCHEMBL4217529 | 0.69 | EPHX2 (0.51) | APPBCHEACHEEPHX2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | APP 1090/4885BCHE 168/4885ACHE 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.